Bibliography
- Wu FC, Tajar A, Beynon JM, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 2010;363:123-35
- Lunenfeld B, Mskhalaya G, Kalinchenko S, et al. Recommendations on the diagnosis, treatment and monitoring of late-onset hypogonadism in men - a suggested update. Aging Male 2013;16:143-50
- Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010;95:2536-59
- Corona G, Rastrelli G, Monami M, et al. Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. Eur J Endocrinol 2011;165:687-701
- Francomano D, Greco EA, Lenzi A, et al. CAG repeat testing of androgen receptor polymorphism: is this necessary for the best clinical management of hypogonadism? J Sex Med 2013;10:2373-81
- Traish AM, Park K, Dhir V, et al. Effects of castration and androgen replacement on erectile function in a rabbit model. Endocrinology 1999;140:1861-8
- Morelli A, Filippi S, Mancina R, et al. Androgens regulate phosphodiesterase type-5 expression and functional activity in corpora cavernosa. Endocrinology 2004;145:2253-63
- Greco EA, Spera G, Aversa A. Combining testosterone and PDE5 inhibitors in erectile dysfunction: basic rationale and clinical evidences. Eur Urol 2006;50:940-7
- Aversa A, Isidori AM, De Martino MU, et al. Androgens and penile erection: evidence for a direct relationship between free testosterone and cavernous vasodilation in men with erectile dysfunction. Clin Endocrinol (Oxf) 2000;53:517-22
- Aversa A, Isidori AM, Spera G, et al. Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction. Clin Endocrinol 2003;58:632-8
- Shamloul R, Ghanem H, Fahmy I, et al. Testosterone therapy can enhance erectile function response to sildenafil in patients with PADAM: a pilot study. J Sex Med 2005;2:559-64
- Buvat J, Montorsi F, Maggi M, et al. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). J Sex Med 2011;8:284-93
- Spitzer M, Basaria S, Travison TG, et al. Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a parallel, randomized trial. Ann Intern Med 2012;157:681-91
- Aversa A, Jannini EA, Maggi M, et al. Effects of testosterone replacement on response to sildenafil citrate. Ann Intern Med 2013;158:569-70
- Corona G, Isidori AM, Buvat J, et al. Testosterone supplementation and sexual function: a meta-analysis study. J Sex Med 2014;11:1577-92
- Giannetta E, Gianfrilli D, Barbagallo F, et al. Subclinical male hypogonadism. Best Pract Res Clin Endocrinol Metab 2012;26:539-50
- Aversa A, Francomano D, Lenzi A. Is testosterone treatment dangerous for the cardiovascular system in older hypogonadal men. Int J Cardiol Metabolic Endocrine 2014;4:1-3
- Aversa A, Bruzziches R, Francomano D, et al. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study. J Sex Med 2011;7:3495-503
- Toma M, McAlister FA, Coglianese EE, et al. Testosterone supplementation in heart failure: a meta-analysis. Circ. Heart Fail 2012;5:315-21
- Corona G, Maseroli E, Maggi M. Injectable testosterone undecanoate for the treatment of hypogonadism. Expert Opin Pharmacother 2014;15:1903-26